Proactive Investors - Run By Investors For Investors

Aquinox Pharmaceuticals shares slump after restructuring plan disclosed

The company said it has approved a restructuring plan to reduce operating costs and better align the company's workforce with the needs of its business.
Aquinox Pharmaceuticals shares slump after restructuring plan disclosed
Shares have tumbled more than 85% in recent weeks on the back of disappointing clinical trial results

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares slumped 5.5% in afternoon trading today after it announced it has approved a restructuring plan to reduce operating costs.

Shares were at US$2.43 on Tuesday, tumbling more than 85% in recent weeks on the back of disappointing clinical trial results from the company's Phase 3 LEADERSHIP 301 clinical trial. The company announced last month that the group’s cystitis drug failed to meet its main goal.

The treatment, oral rosiptor (AQX-1125), did not show a statistically significant reduction in bladder pain, according to the company, which is headquartered in Vancouver,  Canada.

READ: Aquinox Pharmaceuticals to stop development of leading cystitis drug; shares slump

The company announced Tuesday that it has halted all further development activities with rosiptor. 

Under the new restructuring plan, the company has reduced its workforce by 30 employees and closed its office in San Bruno, California.

In connection with the restructuring, the company said that it will incur aggregate restructuring charges of approximately $2.5M related to one-time termination severance payments and other employee-related costs and the shut-down of its San Bruno office.

The firm said the majority of the cash payments related to the personnel-related restructuring charges will be paid during the third quarter of 2018, with the remainder to be paid during the fourth quarter of 2018.

Shares of Aquinox were at US$2.43 in afternoon trading on Tuesday. 

 

View full AQXP profile View Profile

Aquinox Pharmaceuticals, Inc. Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use